Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2021 - Issue 6

Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets Download PDF


, ,
Abstract

Antipsychotic medications can help control the symptoms of schizophrenia. A variety of scientific and demographic factors show the capability to sway the selection of odd neuroleptic medications. Quetiapine Fumarate is indicated for the treatment of schizophrenia and bipolar disorder. Disintegrating agents are materials that are commonly used in the formulation of tablets and hard-shell capsules. Within a short period after administration, drugs should dissolve or disintegrate in the stomach. The most preferred decomposition agent in the making of tablets is starch. The primary purpose of this research was to create a reliable immediate-release tablet formulation of the antipsychotic Quetiapine. Tablets are popular due to their low cost, packaging, and shipping, as well as their greater stability and virtual tamper resistance. Orally administered tablets with a faster disintegration time have a shorter absorption time and higher bioavailability. The goal of the study is to create a stable and physically and chemically compatible generic formulation for treating schizophrenia, as well as a pharmaceutically equivalent instant release tablet for individuals with mental illnesses like schizophrenia and bipolar disorder.

Cite this article
Vancouver
Pingale PL, Boraste SS, Amrutkar SV. Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets. Pharmacophore. 2021;12(6):72-81. https://doi.org/10.51847/qO6nwFnunI
APA
Pingale, P. L., Boraste, S. S., & Amrutkar, S. V. (2021). Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets. Pharmacophore, 12(6), 72-81. https://doi.org/10.51847/qO6nwFnunI

QR code:

Short Link:
Quick Access

Associations

Pharmacophore
ISSN: 2229-5402

Copyright © 2024 Pharmacophore. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.